Devyser Diagnostics AB (Nasdaq: DVYSR) (STO:DVYSR), a provider of genetic test kits for laboratories, on Tuesday declared financial information for its full year from January to December 2022.
The company reported a loss after tax of SEK46.0m, compared to a loss of SEK20.7m in the previous year.
Earnings per share before and after dilution amounted to a loss of SEK2.89 in 2022, versus a loss of SEK1.85 in the year before.
Net sales increased by 35.4% to SEK126.6m, over SEK93.5 in 2021.
Devyser added that its board proposes no dividend for 2022.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva